Navigation Links
New Data Confirm That Use of Levemir Can Limit Weight Gain

ion, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 23,600 employees in 79 countries, and markets its products in 179 countries.

*PREDICTIVE™ stands for Predictable Results and Experience in Diabetes through Intensification and Control to Target: an International Variability Evaluation. It is a large prospective, open-label, non-interventional study involving more than 30,000 juvenile and adult patients with type 1 and type 2 diabetes from 19 countries across the world. This 12-week observational study is evaluating the safety and efficacy of Levemir® (insulin detemir, Novo Nordisk) when used in routine clinical practice. The study was designed to validate the benefits and risks of Levemir® treatment seen in clinical trials, as well as to collect important information on treatment patterns and glycaemic control. PREDICTIVE™ is one of the largest observational studies ever conducted in diabetes and highlights the commitment of Novo Nordisk to enhancing treatment of diabetes and improving the quality of life of those it affects.

References

1 Dornhorst A et al. Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort. Int J Clin Pract 2007; 61(3):523–8

2 Fritsche A, Häring H. At last a weight neutral insulin? Int J Obes Relat Metab Disord 2004; 28 Suppl 2:S41–6

3 Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes – causes, effects and coping strategies. Diabetes, Obesity & Metabolism. DOI: 10.1111/j.1463-1326.2006.00686.x

4 Golay A et al. Effects of we
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
2. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
3. Publication Confirms that EpCAM, the Target for Two of Micromets Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
4. MediQuest Concludes Confirmatory Phase III Study of Raynaud’s Therapy
5. New Data Confirms Significant Improvement of Disease Signs and Symptoms in Patients with Rheumatoid Arthritis
6. Encouraging Clinical Activity of GSKs Novel Cancer Immunotherapeutic Confirmed in Phase II Study in Patients with Most Common Form of Lung Cancer
7. New Research Confirms the Benefit of Extended-Release Dipyridamole Plus ASA for Preventing Recurrent Stroke in Low- and High-Risk Patients
8. New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release Tablets as Effective Treatment for Schizophrenia
9. Positive Clinical Data on CC-10004 Confirms Potential as Novel Oral Approach to Treating Inflammatory Diseases
10. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
11. Efficacy and Safety Profile of Basileas Alitretinoin for Severe Refractory Chronic Hand Eczema Confirmed by Data Shown at European Dermatology Congress
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New Data Confirm That Use Levemir Can Limit Weight Gain
(Date:12/24/2014)... , Dec. 23, 2014 Tianyin Pharmaceutical ... that specializes in patented biopharmaceutical, modernized traditional Chinese ... (API) today announced that the Company achieved the ... Manufacturing Practice (GMP) certificate of TPI,s Qionglai Facility ... (CFDA). The public notice period is a significant ...
(Date:12/24/2014)... and RALEIGH, N.C. , Dec. 23, ... International plc (NASDAQ: ENDP ) (TSX: ENL), ... ) announced today that they have submitted a New ... the U.S. Food and Drug Administration (FDA).  Buprenorphine HCl ... pain severe enough to require daily, around-the-clock, long-term opioid ...
(Date:12/22/2014)... N.J. , Dec. 22, 2014  CytoSorbents ... marketing its CytoSorb® blood purification technology to help ... patients in 28 countries worldwide, today announced the ... , MD, FACS, as its Senior Vice President ... Dr. Di Russo is ...
Breaking Medicine Technology:TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5
... Study Suggests That Ekkyo,s New Approach of LASH ... can Drastically Improve Scar Healing Physiology, MARSEILLES, ... Technology) a photomedicine company, which develops first-in-class,laser-based systems ... publication of a scientific article in Lasers in ...
... M.D., president of SPRI,Clinical Trials, will be a featured ... Group Investor Seminar -- Management,s Guide to,Wall Street. The ... Midtown,Loft & Terrace, 267 Fifth Avenue in New York. ... and small and mid-cap life science companies to gain,better ...
Cached Medicine Technology:Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine" 2Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine" 3
(Date:12/25/2014)... Dec. 24, 2014 (HealthDay News) -- Among early stage ... less than half of one percent will eventually develop ... analysis reveals. The finding comes from a review ... 1998 and 2007, and it suggests that the risk ... what experts had previously thought. "The frequency of ...
(Date:12/25/2014)... 2014 Plugin creators from Pixel Film ... fully customizable business presentation tool made specifically for ... 5k business tool, users can now display their stats ... Pixel Film Studios. “ProFire 5k gives users a multiple ... professionalism to a presentation” , Pixel Film Studios takes ...
(Date:12/24/2014)... Over 700 toys, that’s what AlignLife ... 700 smiling little faces this holiday that might not ... monetary donations was given to the various charities as ... incur through the year. Some of the charities chosen ... , Shrine's Children's Hospitals, Toys for Tots and Crisis ...
(Date:12/24/2014)... Rosa, CA (PRWEB) December 24, 2014 New ... particularly susceptible to hearing loss related depression (March 6, 2014, ... associated with gradual hearing loss (about 50 percent according to ... extremely positive effect on how a person feels and relates ... report that overall improvements are also made by way of:, ...
(Date:12/24/2014)... (PRWEB) December 25, 2014 The report ... 2023” focuses on the current treatment landscape, unmet needs, ... market. Stivarga is a drug which is used in ... is orally administered and is also prescribed to patients ... which is FDA approved is a multi-kinase inhibitor and ...
Breaking Medicine News(10 mins):Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:AlignLife Donates Over 700 Toys This Year 2Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 2Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 3Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 4Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 5Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 6Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3
... intra-aortic balloon pumps prior to angioplasty in patients with ... of heart muscle damage, a condition referred to as ... Duke University Medical Center researchers. The findings ... the American Medical Association ( JAMA ), and ...
... , MONDAY, Aug. 29 (HealthDay News) -- Although older ... may not be making good decisions about their coverage, ... -- particularly those with impaired brain function -- can ... plans available to them, preventing them from finding the ...
... , MONDAY, Aug. 29 (HealthDay News) -- The width ... performs, according to a new study. Researchers compared the ... their companies, financial performance. The study included only men because ... behavior applies only to men. The firms of CEOs ...
... agree that financial constraints and an aging population will require ... find that pushing back the eligibility age could be a ... most. The consequences both positive and negative of ... presented in the latest installment of the Public Policy & ...
... Caution is required when deciding whether to stop life support ... Researchers examined death rates after life support was ... brain injury in six trauma centers in the Canadian provinces ... the patients died in hospital, but the rate varied from ...
... EMPHASIS-HF study showed significant reductions in death and hospitalization ... failure (CHF) and mild symptoms treated with eplerenone in ... and standard therapy. Commenting on the findings presented ... Cardiology Congress (ESC) Hot Line Session on 29th August ...
Cached Medicine News:Health News:Study shows balloon pump use prior to angioplasty does not reduce heart muscle damage 2Health News:Some Older Americans Overwhelmed by Medicare Options, Study Says 2Health News:Some Older Americans Overwhelmed by Medicare Options, Study Says 3Health News:Aging authorities differ on tweaks to Social Security's benefit structure 2Health News:Use Caution in Ending Life Support for Brain-Injured, Experts Say 2Health News:The effect of eplerenone vs. placebo on cardiovascular mortality 2Health News:The effect of eplerenone vs. placebo on cardiovascular mortality 3
The Guidant Fineline II Sterox Atrial J is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
The Guidant Fineline II Sterox is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
Steroid eluting pacemaker leads...
VascoStim B 2/5F is a bipolar temporary pacing lead with a balloon. It can be placed easily by the resistance of the inflated balloon in the blood flow....
Medicine Products: